engleski

Plasma adropin levels in patients with moderate and severe obstructive sleep apnea

Objectives: Many studies showed different metabolic and inflammatory alterations in patients with obstructive sleep apnea (OSA), but the role of adropin, novel peptide included in energy homeostasis, remains undetermined in this population. Therefore, the aim of this study was to investigate plasma adropin levels in patients with moderate OSA (apnea-hypopnea index (AHI): 15–30) and severe OSA (AHI > 30) patients, compared to control subjects. Methods: In this study we included 56 OSA patients (24 moderate and 32 severe) and 20 age-sex matched control subjects. Plasma adropin levels were assayed using a commercial enzyme-linked immunosorbent assay kit (Phoenix Pharmaceuticals Inc., Burlingame, CA, USA). The data were compared using ANOVA with Tukey post-hoc test and the Pearson’s correlation analysis. The level of significance was set at P < 0.05. Results: Plasma adropin levels were significantly lower in severe OSA group compared with moderate OSA and control groups (4.34 ± 1.50 vs. 6.58 ± 1.84 vs. 7.95 ± 1.69 ng/mL, P < 0.001). Significant negative correlations were found between plasma adropin levels and AHI (r = –0.519, P < 0.001), as well as oxygen desaturation index (ODI) (r = –0.481, P = 0.002). Conclusion: In conclusion, our study showed that plasma adropin levels were significantly lower in severe OSA patients, compared with moderate OSA patients and controls. Additionally, the results of this study suggest the positive association of plasma adropin levels and the severity of OSA.

plasma adropin ; obstructive sleep apnea ; patients

nije evidentirano